Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain
- PMID: 23369054
- DOI: 10.1586/ern.13.4
Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain
Abstract
Spasticity is a disabling complication of multiple sclerosis. Some commonly used oral medications include baclofen, tizanidine, anticonvulsants and benzodiazepines, but their benefits are modest. Sativex® (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain) is a unique cannabinoid-based medicine with two main active ingredients; 9-δ-tetrahydrocannabinol, which acts mainly on cannabinoid 1 receptors in the CNS and plays a key role in the modulation of spasticity and spasms, and cannabidiol, which has different properties, including minimization of the psychoactivity associated with 9-δ-tetrahydrocannabinol. Sativex is indicated for symptomatic improvement in adult patients with moderate-to-severe multiple sclerosis-related spasticity who have not responded adequately to other first- or second-line antispasticity medications, and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy. Over the past couple of years, Sativex has been approved for use in a number of European countries and ongoing postmarketing studies are evaluating the possible risks associated with Sativex treatment by systematically collecting all suspected adverse reactions that occur in patients from the start of treatment. Interim data from the UK as well as Spanish Sativex safety registries confirm that clinical benefit is maintained over the longer term despite the expected trend for deterioration owing to disease progression. Even after more than 2 years of use, no new safety/tolerability signals have emerged with Sativex, including no evidence of driving impairment and no relevant incidence of falls or other adverse events of concern, such as psychiatric or nervous system events. Sativex appears to be a well-tolerated and useful add-on therapy in patients who have not achieved an adequate response with traditional antispastic agents.
Similar articles
-
A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):15-9. doi: 10.1586/ern.13.1. Expert Rev Neurother. 2013. PMID: 23369055 Review.
-
Multiple sclerosis spasticity symptoms management. Endocannabinoid system modulator data beyond clinical trials. Foreword.Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):1. doi: 10.1586/ern.13.2. Expert Rev Neurother. 2013. PMID: 23369052 No abstract available.
-
Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Expert Rev Neurother. 2013. PMID: 24289844 Review.
-
Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.Drugs. 2014 Apr;74(5):563-78. doi: 10.1007/s40265-014-0197-5. Drugs. 2014. PMID: 24671907 Review.
-
Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.J Comp Eff Res. 2014 Jul;3(4):435-44. doi: 10.2217/cer.14.30. J Comp Eff Res. 2014. PMID: 25275238 Review.
Cited by
-
Effectiveness, Safety and Patients' Satisfaction of Nabiximols (Sativex®) on Multiple Sclerosis Spasticity and Related Symptoms in a Swiss Multicenter Study.J Clin Med. 2024 May 14;13(10):2907. doi: 10.3390/jcm13102907. J Clin Med. 2024. PMID: 38792448 Free PMC article.
-
Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol.Arh Hig Rada Toksikol. 2020 Mar 1;71(1):1-11. doi: 10.2478/aiht-2020-71-3301. Arh Hig Rada Toksikol. 2020. PMID: 32597140 Free PMC article. Review.
-
Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies.J Cent Nerv Syst Dis. 2019 Mar 11;11:1179573519831997. doi: 10.1177/1179573519831997. eCollection 2019. J Cent Nerv Syst Dis. 2019. PMID: 30886530 Free PMC article. Review.
-
Therapeutic potential of medicinal marijuana: an educational primer for health care professionals.Drug Healthc Patient Saf. 2018 Jun 11;10:45-66. doi: 10.2147/DHPS.S158592. eCollection 2018. Drug Healthc Patient Saf. 2018. PMID: 29928146 Free PMC article. Review.
-
Interaction of Plant Extracts with Central Nervous System Receptors.Medicines (Basel). 2017 Feb 23;4(1):12. doi: 10.3390/medicines4010012. Medicines (Basel). 2017. PMID: 28930228 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous